Clinical Trial

Electroacupuncture for Cognitive Toxicity in Cancer Survivors: Assessing Implementation, Cost, and Effectiveness for Integration

Study acronym: EAST-ALIGN
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to evaluate the clinical effectiveness and understand the biological mechanisms of electroacupuncture (EA) in reducing cognitive toxicity among cancer survivors. The study aims are: * To evaluate the clinical effectiveness of a 10-week EA regimen targeting neuropsychiatric-related acupoints in reducing cognitive toxicity among cancer survivors in Singapore. * To explore the biological mechanisms underlying EA's effects on cognitive function. * To assess the early implementation of EA for managing cognitive toxicity in cancer survivors. Researchers will compare results from the true EA arm, sham EA arm and waitlist control arm, to see if electroacupuncture can help improve cognitive issues related to cancer and its treatment, how it may work, and what factors may affect how it is delivered in cancer care. Participants will: * Be assigned to either of the 3 arms (true EA, sham EA, waitlist control) * Received 10 EA sessions (if assigned to true or sham EA arm) * Complete 3 study assessment visits at baseline, Week 13, and Week 17 * Be invited to a one-time interview to share their study experience (optional, if selected)
Trial Details
NCT Number NCT07583979
Lead Sponsor National Cancer Centre, Singapore
Collaborators: Singapore Thong Chai Medical Institution
Conditions Cancer-related Cognitive Impairment
Enrollment 168 participants
Start Date 2026-07-01
Primary Completion 2028-10-31 (estimated)
Study Completion 2029-01-13 (estimated)
Updated on ClinicalTrials.gov 2026-05-13